These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 34984740)

  • 21. Utilization of gynecologic services in women with breast cancer receiving hormonal therapy.
    Wright JD; Desai VB; Chen L; Burke WM; Tergas AI; Hou JY; Accordino M; Ananth CV; Neugut AI; Hershman DL
    Am J Obstet Gynecol; 2017 Jul; 217(1):59.e1-59.e12. PubMed ID: 28341383
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aromatase inhibitor and tamoxifen use and the risk of venous thromboembolism in breast cancer survivors.
    Xu X; Chlebowski RT; Shi J; Barac A; Haque R
    Breast Cancer Res Treat; 2019 Apr; 174(3):785-794. PubMed ID: 30659431
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.
    Gibson LJ; Dawson C; Lawrence DH; Bliss JM
    Cochrane Database Syst Rev; 2007 Jan; (1):CD003370. PubMed ID: 17253488
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiovascular Disease After Aromatase Inhibitor Use.
    Haque R; Shi J; Schottinger JE; Chung J; Avila C; Amundsen B; Xu X; Barac A; Chlebowski RT
    JAMA Oncol; 2016 Dec; 2(12):1590-1597. PubMed ID: 27100398
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
    Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W
    Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimal duration of endocrine therapy with extended aromatase inhibitors for postmenopausal patients with hormone receptor-positive breast cancer: a meta-analysis.
    Chen J; Zhang X; Lu Y; Zhang T; Ouyang Z; Sun Q
    Breast Cancer; 2021 May; 28(3):630-643. PubMed ID: 33387283
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Incident comorbidities after tamoxifen or aromatase inhibitor therapy in a racially and ethnically diverse cohort of women with breast cancer.
    Gupta T; Purington N; Liu M; Han S; Sledge G; Schapira L; Kurian AW
    Breast Cancer Res Treat; 2022 Nov; 196(1):175-183. PubMed ID: 36030472
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aromatase inhibitors and the incidence of Parkinson disease: A population-based cohort study.
    Khosrow-Khavar F; Azoulay L; Montastruc JL; Montastruc F; Renoux C
    Cancer; 2022 Jun; 128(12):2339-2347. PubMed ID: 35363379
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative assessment of lipid effects of endocrine therapy for breast cancer: implications for cardiovascular disease prevention in postmenopausal women.
    Esteva FJ; Hortobagyi GN
    Breast; 2006 Jun; 15(3):301-12. PubMed ID: 16230014
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of exercise on physical outcomes of breast cancer survivors receiving hormone therapy - A systematic review and meta-analysis.
    Boing L; Vieira MCS; Moratelli J; Bergmann A; Guimarães ACA
    Maturitas; 2020 Nov; 141():71-81. PubMed ID: 33036706
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trials.
    Cuppone F; Bria E; Verma S; Pritchard KI; Gandhi S; Carlini P; Milella M; Nisticò C; Terzoli E; Cognetti F; Giannarelli D
    Cancer; 2008 Jan; 112(2):260-7. PubMed ID: 18041059
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effects of adjuvant endocrine therapy on bone health in women with breast cancer.
    Ramchand SK; Cheung YM; Yeo B; Grossmann M
    J Endocrinol; 2019 Jun; 241(3):R111-R124. PubMed ID: 30991355
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case-control study.
    Le Ray I; Dell'Aniello S; Bonnetain F; Azoulay L; Suissa S
    Breast Cancer Res Treat; 2012 Sep; 135(2):603-9. PubMed ID: 22903687
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aromatase inhibitors and risk of cardiovascular events in breast cancer patients: a systematic review and meta-analysis.
    He Y; Zhang J; Shen G; Liu L; Zhao Q; Lu X; Yang H; Hong D
    BMC Pharmacol Toxicol; 2019 Oct; 20(1):62. PubMed ID: 31665091
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trial.
    Rabaglio M; Sun Z; Maibach R; Giobbie-Hurder A; Ejlertsen B; Harvey VJ; Neven P; Láng I; Bonnefoi H; Wardley A; Ruepp B; Castiglione M; Coates AS; Gelber RD; Goldhirsch A; Colleoni M; Thürlimann B; Regan MM
    Breast Cancer Res Treat; 2021 Feb; 185(3):697-707. PubMed ID: 33159633
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Medication Use for the Risk Reduction of Primary Breast Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Nelson HD; Fu R; Zakher B; Pappas M; McDonagh M
    JAMA; 2019 Sep; 322(9):868-886. PubMed ID: 31479143
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Adjuvant endocrine therapy in breast cancer. Management of early-risk relapse].
    Chahine G; Howayek M; Atallah D
    J Med Liban; 2009; 57(2):124-9. PubMed ID: 19623889
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The association between endocrine therapy use and osteoporotic fracture among post-menopausal women treated for early-stage breast cancer in Ontario, Canada.
    Blanchette PS; Lam M; Le B; Richard L; Shariff SZ; Ouédraogo AM; Pritchard KI; Raphael J; Vandenberg T; Fernandes R; Desautels DN; Chan KKW; Earle CC
    Breast; 2021 Dec; 60():295-301. PubMed ID: 34728119
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer.
    Perez EA
    Ann Oncol; 2007 Sep; 18 Suppl 8():viii26-35. PubMed ID: 17890211
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.